Drug Information

Drug General Information
Drug ID
D04INS
Former ID
DIB004813
Drug Name
Long-acting exenatide
Synonyms
HM-11260C; LAPS-Exendin; LAPS-Exendin-4; Long-acting exenatide (LAPS, type 2 diabetes); Long-acting exenatide (LAPS, type 2 diabetes), Hanmi; DM-exendin-4(Lys27)-PEG-Fc; Long-acting exendin-4 analog (LAPS, type 2 diabetes), Hanmi; Des-amino-histidyl exendin-4(Lys)-PEG-immunoglobulin Fc
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 2 [530376], [532841], [551186]
Company
Hanmi pharmaceutical
Structure
Download
2D MOL

3D MOL
Canonical SMILES
N1(C(=O)[C@H]2N(C(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[<br />C@@H](NC(=O)[C@H]3N(C(=O)CNC(=O)CNC(=O)[C@H](CC(=O)N)CC<br />(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O<br />)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@<br />@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]<br />(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC<br />(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O<br />)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CN)CCC(=<br />O)O)[C@H](O)C)Cc4ccccc4)[C@H](O)C)CO)CC(=O)O)CC(C)C)CO)<br />CCCCN)CCC(=O)N)CCSC)CCC(=O)O)CCC(=O)O)CCC(=O)O)C)C(C)C)<br />CCCNC(=N)N)CC(C)C)Cc4ccccc4)[C@H](CC)C)CCC(=O)O)Cc4c[nH<br />]c5c4cccc5)CC(C)C)CCCCNC(=O)*)CCC3)CO)CO)C)CCC2)[C@H](C<br />(=O)N2[C@H](C(=O)N[C@H](C(=O)N)CO)CCC2)CCC1
Target and Pathway
Target(s) Glucagon-like peptide 1 receptor Target Info Agonist [530376], [532841]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Insulin secretion
Reactome Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
G alpha (s) signalling events
Glucagon-type ligand receptors
WikiPathways GPCRs, Class B Secretin-like
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 530376Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77.
Ref 532841Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9.
Ref 5511862005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
Ref 530376Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77.
Ref 532841Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.